Here are five insights:
1. Orthofix reported earnings per share guidance of $1.54 to $1.63.
2. The company’s revenue guidance is $428 million to $431 million.
3. Orthofix’s stock carries a market capitalization of $976.27 million.
4. The company’s stock has a P/E ratio of $125.83.
5. The 50-day moving average price is $49.01 and the 200-day moving average is $45.60.
More articles on biologics:
Pinnacle Spine Group files for FDA clearance of InFill Lateral Fusion System: 4 points
Dr. Abba Zubair researches whether stem cells grow faster in space: 5 highlights
AngelMD’s venture capital fund supports bone biologic startup with 2nd investment: 6 takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
